Abstract
The application of ligand-based drug design methods such as quantitative structure–activity relationship (QSAR) is a mandatory issue in the design of luteinizing hormone-releasing hormone (LHRH) receptor antagonists because the lack of information on the molecular structure for this target protein. The relationship between the structures and the antagonistic activities of 128 non-peptide antagonists for the LHRH receptor were modeled by using the classic QSAR methods comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). The best model included CoMSIA steric, electrostatic, hydrophobic and hydrogen bond donor fields, had a Q2 value of 0.780 and predicted adequately the activity of external compounds. The tridimensional contour maps generated were used to identify the key structural requirements responsible for a high biological activity of the compounds. These features should represent the ligand features involved in interactions with the target protein that modulate their potency as antagonists.
Keywords: Non-peptide LHRH antagonists, QSAR, CoMSIA
Medicinal Chemistry
Title:3D-QSAR Modeling of Non-peptide Antagonists for the Human Luteinizing Hormone-releasing Hormone Receptor
Volume: 9 Issue: 4
Author(s): Alain Tundidor-Camba, Julio Caballero and Deysma Coll
Affiliation:
Keywords: Non-peptide LHRH antagonists, QSAR, CoMSIA
Abstract: The application of ligand-based drug design methods such as quantitative structure–activity relationship (QSAR) is a mandatory issue in the design of luteinizing hormone-releasing hormone (LHRH) receptor antagonists because the lack of information on the molecular structure for this target protein. The relationship between the structures and the antagonistic activities of 128 non-peptide antagonists for the LHRH receptor were modeled by using the classic QSAR methods comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). The best model included CoMSIA steric, electrostatic, hydrophobic and hydrogen bond donor fields, had a Q2 value of 0.780 and predicted adequately the activity of external compounds. The tridimensional contour maps generated were used to identify the key structural requirements responsible for a high biological activity of the compounds. These features should represent the ligand features involved in interactions with the target protein that modulate their potency as antagonists.
Export Options
About this article
Cite this article as:
Tundidor-Camba Alain, Caballero Julio and Coll Deysma, 3D-QSAR Modeling of Non-peptide Antagonists for the Human Luteinizing Hormone-releasing Hormone Receptor, Medicinal Chemistry 2013; 9(4) . https://dx.doi.org/10.2174/1573406411309040010
DOI https://dx.doi.org/10.2174/1573406411309040010 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives
Current Medicinal Chemistry Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer
Current Cancer Drug Targets The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces
Current Molecular Medicine Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences Glucose Transport and Metabolism in Sertoli Cell: Relevance for Male Fertility
Current Chemical Biology MicroRNAs and Diabetes Mellitus Type 1
Current Diabetes Reviews Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?
Current Pharmaceutical Design The ERp57/GRp58/1,25D3-MARRS Receptor: Multiple Functional Roles in Diverse Cell Systems
Current Medicinal Chemistry Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of High-intensity Focused Ultrasound in the Management of Extra-abdominal Desmoid Tumors
Current Medical Imaging Neuroimmunomodulation and Aging: A Role for Transferrin and the Hypothalamus/Thymus Axis
Current Aging Science